Liquidia to Present at the 2020 Jefferies Virtual London Healthcare Conference
November 12 2020 - 9:06AM
Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage
clinical biopharmaceutical company focused on the development and
commercialization of novel products utilizing its proprietary
PRINT® technology, today announced that Neal Fowler, Chief
Executive Officer of Liquidia, will present at the 2020 Jefferies
Virtual London Healthcare Conference at 7:55 PM GMT (2:55 PM ET) on
Thursday, November 19, 2020.
A link to the live audio webcast and replay of the presentation
will be available on the Events & Presentations page
of the Company’s corporate website, and will be archived for a
minimum of 90 days.
About Liquidia
Liquidia is a late-stage clinical biopharmaceutical company
focused on the development and commercialization of novel products
using its proprietary PRINT® technology to transform the lives of
patients. PRINT is a particle engineering platform that enables
precise production of uniform drug particles designed to improve
the safety, efficacy and performance of a wide range of therapies.
Currently, Liquidia is focused on the development of two
product candidates for which it holds worldwide commercial rights:
LIQ861 for the treatment of pulmonary arterial hypertension (PAH)
and LIQ865 for the treatment of local post-operative
pain. Liquidia is headquartered in Research Triangle
Park, NC. For more information, please
visit www.liquidia.com.
Contact Information
Investor Relations: Jason AdairVice President,
Corporate Development and
Strategy919.328.4400jason.adair@liquidia.com
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Apr 2024 to May 2024
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From May 2023 to May 2024